Oncternal Therapeutics
1042-B North El Camino Real
Encinitas, CA 92024
Encinitas, CA 92024
Encinitas, CA 92024
United States
Tel: 858-434-1113
Fax: 858-408-3010
Website: http://www.oncternal.com/
Email: info@oncternal.com
152 articles about Oncternal Therapeutics
-
Oncternal Therapeutics Hosting Key Opinion Leader Webinar on Hematological Malignancies and Prostate Cancer
1/20/2022
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will host a key opinion leader (KOL) webinar on hematological malignancies and prostate cancer on Tuesday, January 25, 2022 from 2:30 - 4:30 pm (ET).
-
Oncternal Therapeutics Announces Agreement with U.S. FDA on Phase 3 Registrational Study Design for Zilovertamab in the Treatment of Mantle Cell Lymphoma
1/4/2022
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), today announced that following a successful End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) for zilovertamab.
-
Oncternal Therapeutics Presents Updated Interim Data for Zilovertamab in Combination with Ibrutinib at ASH 2021
12/13/2021
Oncternal Therapeutics, Inc. today announced updated interim clinical data from the ongoing Phase 1/2 CIRLL (Cirmtuzumab and Ibrutinib targeting ROR1 for Leukemia and Lymphoma) clinical trial, that will be presented in a poster presentation at the American Society of Hematology (ASH) 2021 Annual Meeting.
-
Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - Dec 01, 2021
12/1/2021
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, announced that it has granted an inducement award to one new employee, Carina Freedman, who joined the Company as Clinical Trial Manager.
-
Oncternal Therapeutics Presented Updated Interim Phase 1/2 Clinical Trial Data for ONCT-216 in Patients with Relapsed/Refractory Ewing Sarcoma at CTOS 2021 Virtual Annual Meeting
11/15/2021
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), today announced updated interim clinical data from the Phase 2 expansion cohort of its ongoing Phase 1/2 clinical trial evaluating ONCT-216 (formerly TK216), an investigational, potentially first-in-class, targeted small-molecule inhibitor of the E26 transformation-specific (ETS) family of oncoproteins, in patients with relapsed or refractory Ewing sarcoma.
-
Oncternal Therapeutics to Present at the 12th Annual Jefferies London Healthcare Conference
11/9/2021
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, announced that management will present and participate virtually at the 12th Annual Jefferies London Healthcare Conference.
-
Oncternal Provides Business Update and Announces Third Quarter 2021 Financial Results
11/4/2021
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, reported financial results for the third quarter of 2021.
-
Oncternal Therapeutics Joins Karolinska Institutet’s NextGenNK Competence Center for the Development of Next Generation NK Cell-Based Cancer Immunotherapies
11/3/2021
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), today announced it has joined Karolinska Institutet’s NextGenNK Competence Center for the Development of Next Generation NK Cell-Based Cancer Immunotherapies as a collaborative partner.
-
Oncternal Therapeutics Announces Formation of Cell Therapy Scientific Advisory Board
11/2/2021
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the establishment of its Cell Therapy Scientific Advisory Board (SAB).
-
Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - Nov 01, 2021
11/1/2021
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, announced that it has granted an inducement award to one new employee, Mohab Hassanin, who joined the Company as Clinical Trial Manager.
-
Oncternal Therapeutics to Provide Business Update and Report Third Quarter 2021 Financial Results
10/29/2021
Oncternal Therapeutics, Inc. today announced that it will report third quarter 2021 financial results after the U.S. financial markets close on Thursday, November 4, 2021.
-
Oncternal Therapeutics Announced Pre-Clinical Data from ONCT-534, an Androgen Receptor N-Terminal-Domain-Binding Small Molecule Degrader, Was Accepted for Virtual Poster Presentation at AACR-NCI-EORTC Virtual International Conference
10/5/2021
Oncternal Therapeutics, Inc. announced pre-clinical data from ONCT-534, an androgen receptor N-terminal-domain-binding small molecule degrader, was accepted for virtual poster presentation at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics on October 7-10, 2021.
-
Oncternal Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
10/1/2021
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it has granted inducement awards to Emily Samec, who joined the Company as Vice President, Operations and Project Management, and 3 new non-executive employees.
-
Oncternal Therapeutics to Participate in September 2021 Investor Conferences
9/9/2021
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, announced that management will participate in the following conferences in the month of September/
-
Oncternal Therapeutics Rounds Out Leadership Team with Appointment of Steven Hamburger, Ph.D. as Senior Vice President, Regulatory Affairs and Quality Assurance
9/1/2021
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the appointment of Steven Hamburger, Ph.D. as Senior Vice President of Regulatory Affairs and Quality Assurance.
-
Oncternal Provides Business Update and Announces Second Quarter 2021 Financial Results
8/5/2021
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, reported financial results for the second quarter of 2021.
-
Oncternal Therapeutics to Participate in the BTIG Virtual Biotechnology Conference
8/2/2021
Oncternal Therapeutics, a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, announced that management will participate in the BTIG Virtual Biotechnology Conference being held August 9-10, 2021.
-
Oncternal Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Aug 02, 2021
8/2/2021
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, announced that it has granted inducement awards to two new non-executive employees.
-
Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2021 Financial Results
7/29/2021
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report second quarter 2021 financial results after the U.S. financial markets close on Thursday, August 5, 2021.
-
Oncternal Therapeutics Appoints Pablo Urbaneja as Sr. Vice President, Corporate Development
7/1/2021
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the appointment of Pablo Urbaneja as Senior Vice President, Corporate Development.